Results 211 to 220 of about 76,021 (334)

Mineralocorticoid Receptor-Dependent Adverse Remodeling After Myocardial Infarction Mediated by uNGALant Activation of NFκB [PDF]

, 2017
Johann Bauersachs, Daniela Fraccarollo
openalex   +1 more source

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1105-1115, February 2026.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source

Licorice-Induced Pseudohyperaldosteronism Highlights an Underestimated Etiology of Hypertension. [PDF]

Kidney Int Rep
Bendjilali-Sabiani JJ, Cardinale A, Lamy A, Pouget AM, Boyer JC, Taillard V, Reboul P.   +6 more
europepmc   +1 more source

The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health

Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, M Bara, Katarzyna Herjan, Piotr Armański   +5 more
openalex   +2 more sources

Sub-chronic stimulation of glucocorticoid receptor impairs and mineralocorticoid receptor protects cytosolic Ca2+ responses to glucose in pancreatic β-cells [PDF]

, 2008
Masaru Koizumi, Toshihiko Yada
openalex   +1 more source

Cortisol as mineralocorticoid [PDF]

Journal of Clinical Endocrinology & Metabolism, 1996
openaire   +2 more sources

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Dickkopf 3 in Urine: A Help for Prioritizing Management of Kidney Disease in Type 2 Diabetes. [PDF]

Diabetes
Rossing P.
europepmc   +1 more source

Human mineralocorticoid receptor interacts with actin under mineralocorticoid ligand modulation [PDF]

, 1996
Stéphan Jalaguier, Dominique Mornet, Danielle Mesnier, Jean Léger, Gilles Auzou   +4 more
openalex   +1 more source

The biology of PKM2 in the metabolism and senescence in diabetic kidney disease

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 197-204, February 2026.
ABSTRACT Diabetic kidney disease (DKD) is one of the most common causes of chronic kidney disease that leads to end‐stage kidney disease, and its progression is closely linked to metabolic stress within renal tubular cells. Under long‐term hyperglycemia, cells shift their glucose metabolism from normal oxidative phosphorylation toward glycolysis.
Md. Imrul Kayes, Keizo Kanasaki
wiley   +1 more source